Similar Search Results

Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation?

Grootendorst, Paul - Department of Economics, McMaster University - 2009

The question as to how society should support pharmaceutical (‘pharma’) innovation is both pertinent and timely: Pharma drugs are an integral component of modern health care and hold the promise to treat more effectively various debilitating health problems. The productivity of the pharma...

Persistent link: https://www.econbiz.de/10005013021

How should we support pharmaceutical innovation?

Grootendorst, Paul - Department of Economics, McMaster University - 2009

Persistent link: https://www.econbiz.de/10005051492

Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs

Alan, Sule; Crossley, Thomas F.; Grootendorst, Paul; … - Department of Economics, McMaster University - 2002

Canadian household prescription drug expenditures are studied using different years of the Statistics Canada Family Expenditure Survey. Master files are used, expanding the number of available years and permitting provincial rather than regional identifiers. Nonparametric Engel curves are...

Persistent link: https://www.econbiz.de/10005181103

Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population

Grootendorst, Paul; Levine, Mitchell - Department of Economics, McMaster University - 2002

The 1984 Canada Health Act does not require that the provinces subsidize prescription drugs. Many provinces do, however, provide categorical coverage to the elderly, social assistance recipients and others, although the generosity of coverage is highly variable. A system of parallel private...

Persistent link: https://www.econbiz.de/10005181125

Effects of 'Authorized-Generics' on Canadian Drug Prices

Grootendorst, Paul - Department of Economics, McMaster University - 2007

generic competitors should lower prices. On the other hand, the threat of AG entry into a therapeutic market might deter entry … of AG entry into a market might deter entry by IGs. IG executives, however, state that the threat of AG entry has … decreased their incentive to challenge ‘marginal’ drug markets. In particular the threat of AG entry has increased from $5m to …

Persistent link: https://www.econbiz.de/10005404411

The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada

Crossley, Thomas F.; Grootendorst, Paul; Korkmaz, Sule; … - Department of Economics, McMaster University - 2000

Between 1970 and 1986 all Canadian provinces introduced some version of a prescription drug subsidy for those age 65 or over and since 1986, all the provinces have increased copayments or deductibles to some degree. Employing a first-order approximation to the welfare gains from a subsidy, we...

Persistent link: https://www.econbiz.de/10005404436

The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature

Grootendorst, Paul; Piérard, Emmanuelle; Shim, Minsup - Department of Economics, McMaster University - 2007

Several studies suggest that, on the basis of life expectancy (LE) regressions, new pharmaceutical drugs are responsible for some of the marked gains in LE observed over the last 50 years. We critically appraise these studies. We point out several modeling issues, including disentangling the...

Persistent link: https://www.econbiz.de/10005635177

Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs

Alan, Sule; Crossley, Thomas F.; Grootendorst, Paul; … - Department of Economics, McMaster University - 2002

Persistent link: https://www.econbiz.de/10005635196

The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada

Crossley, Thomas F.; Grootendorst, Paul; Korkmaz, Sule; … - Department of Economics, McMaster University - 2000

Persistent link: https://www.econbiz.de/10005635316